Buy Invega (Paliperidone) atypical antipsychotic medication online
Cheap qualitative Paliperidone 3 mg, 6 mg extended-release tablets
HOW AND WHERE TO ORDER PALIPERIDONE (INVEGA) 3 MG, 6 MG TABLETS OR CAPSULES ONLINE:
INVEGA: DRUG INTERACTIONS
Potential for Invega to affect other drugs
Given the primary CNS effects of paliperidone, Paliperidone (Invega) should be used with caution in combination with other centrally acting drugs and alcohol. Paliperidone may antagonize the effect of levodopa and other dopamine agonists.
Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when Invega is administered with other therapeutic agents that have this potential.
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
Paliperidone (Invega) is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations. No in vivo data are available and the clinical relevance is unknown.
Pharmacokinetic interaction between lithium and Invega is unlikely.
In a drug interaction study, co-administration of Invega (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics (AUC24h and Cmax,ss) of valproate in 13 patients stabilized on valproate. In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when Invega (Paliperidone) 3-15 mg per day was added to their existing valproate treatment.
Potential for other drugs to affect Invega
Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
Co-administration of Invega (Paliperidone) 6 mg once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of Invega should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of INVEGA should be re-evaluated and decreased if necessary.
Paliperidone (Invega) is metabolized to a limited extent by CYP2D6. In an interaction study in healthy subjects in which a single 3 mg dose of Invega was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.
Co-administration of a single dose of Invega (Paliperidone) 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone. Dosage reduction for Invega should be considered when this medication is co-administered with valproate after clinical assessment.
Pharmacokinetic interaction between lithium and Invega (Paliperidone) is unlikely.
Paliperidone (Invega) related pharmaceutical drugs and medications
|Trade name of the drug
||Pharmaceutical forms and doses
|Orap drug interactions
||Tablets; Oral; Pimozide 10 mg
||Tablets; Oral; Buspirone Hydrochloride 10 mg
Buy Invega (Paliperidone) Online
Invega prescribing information
Disclaimer: Please note, this website is not an online pharmacy, drugstore and related online pharma shop. It does not sell, supply or advertise any prescription and OTC drugs, medications, other goods and services. All reviews, links, lists, databases, texts, and other content on the website are provided free and only for informational and educational purposes. Medical content on this website, including drug names, indications, contraindication, side effects, categories, classifications, forms, doses, prices, other health and pharmaceutical information are taken only from trusted and authoritative professional sources (see "References"), reviewed and prepared by our licensed experts, content inspectors and editors.
You should always consult your doctor or other healthcare professional before using any medication. This website, our staff and support do not provide own medical instructions and advices.
All brands and trade names appearing on the website are registered trademarks of their respective companies.
Remember that buying drugs and medicines online is a responsibility only of customers, sellers and suppliers regarding existing legislation in their jurisdictions.
Share us in social media:
Copyright © 2016-2020 Paliperidone.onlinebuy2.in, a division of Pharma-Doctor.com pharmaceutical network. All rights reserved.
Home Page |
Cookies Policy |
Terms of Service |